Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Ocumension Therapeutics (1477.HK)

HKSE - HKSE Delayed Price. Currency in HKD
Add to watchlist
14.740-0.160 (-1.07%)
At close: 04:08PM HKT
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close14.900
Open14.880
Bid14.740 x N/A
Ask14.780 x N/A
Day's Range14.680 - 14.880
52 Week Range13.920 - 32.050
Volume99,000
Avg. Volume363,135
Market Cap9.828B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMar 19, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.42
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 1477.HK

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • PR Newswire

      Ocumension Acquires all the Equity Interests in Two Ophthalmic Products Mainland China, Further Enhancing its Pipeline Strength

      Beijing time, August 24, 2021, Ocumension Therapeutics announced that it has entered into a product acquisition agreement with a leading global pharmaceutical company Novartis, pursuant to which the Company will acquire all the equity interests in two ophthalmic drugs, Emadine® (Emedastine Difumarate Eye Drops) and Betopic® S (Betaxolol Hydrochloride Eye Drops), in Mainland China and obtain the transfer of the corresponding manufacturing technology. Ocumension's ophthalmic drug pipeline will be

    • PR Newswire

      Ocumension Therapeutics Announces 2021 Interim Results

      The Chinese ophthalmology platform company, Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, the "Group" , stock code: 1477.HK), announced its interim results for the 6 months ended 30 June 2021 (the "Reporting Period").

    • GlobeNewswire

      OPKO Health to Develop and Commercialize RAYALDEE® in Greater China with Nicoya Therapeutics

      MIAMI, June 21, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its subsidiary EirGen Pharma has entered into an agreement with Nicoya Macau Limited, an affiliate of Nicoya Therapeutics (Nicoya), for the development and commercialization in Greater China (mainland China, Hong Kong, Macau and Taiwan) of RAYALDEE® for the treatment of secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD). Nicoya is a leading biotechnology comp

    Advertisement
    Advertisement